FOLH1 and prostate cancer: In their retrospective study, the authors analyzed prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) scans of 451 patients over 2 yr and found that all 74 patients with a PSMA standardized uptake value (SUVmax) value of ≥16 had clinically significant prostate cancer (csPC).